STAT3 and Miyoshi myopathy: Therefore, hyperactivity of STAT3 in HD-MM suggests an important therapeutic target for several STAT3 inhibitors, including peptide-mimetics, small molecule inhibitors and oligonucleotides, presently in pre-clinical and clinical development [55, 56].